Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 10;5(10):100711.
doi: 10.1016/j.xkme.2023.100711. eCollection 2023 Oct.

Tolvaptan, Kidney Function Decline, and Potential Confounding by Muscle Wasting

Dion Groothof  1 , Adrian Post  1 , Stephan J L Bakker  1
Affiliations

Tolvaptan, Kidney Function Decline, and Potential Confounding by Muscle Wasting

Dion Groothof et al. Kidney Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Theoretical distributions of 24-hour urinary volume after 3 weeks of tolvaptan stratified by eGFRcr. The graph depicts density values for 24-hour urinary volume ranging from 0-14 liters per 24 hours, which were calculated based on a set of normal distributions. The means and standard deviations for these distributions were derived from a previous study that reported the 24-hour urinary volume outcomes after 3 weeks of treatment with tolvaptan, stratified by eGFRcr categories (>60, 30-60, and <30 mL/min/1.73 m2). The various levels of transparency in the area under each curve represent the likelihood of observing a particular urinary volume; the more transparent the area, the lower the likelihood it will be observed. Cr, creatinine; eGFR, estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Chebib F.T., Zhou X., Garbinsky D., et al. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023;5(6) - PMC - PubMed
    1. Levey A.S., Inker L.A., Matsushita K., et al. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the national kidney foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–835. - PubMed
    1. Kramers B.J., van Gastel M.D.A., Boertien W.E., Meijer E., Gansevoort R.T. Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis. 2019;73(3):354–362. - PubMed
    1. Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. - PMC - PubMed
    1. Vandewoude M.F.J., Alish C.J., Sauer A.C., Hegazi R.A. Malnutrition-sarcopenia syndrome: is this the future of nutrition screening and assessment for older adults? J Aging Res. 2012;2012 - PMC - PubMed

LinkOut - more resources